NFKB1 and Miyoshi myopathy: Bortezomib, a proteasome inhibitor, has shown activity in pre-clinical models of MM, acting via mechanisms including the inhibition of angiogenesis and NF-κB, the latter having been reported as a crucial cellular effector of chemoresistance in MM [127].